Fresia G. Pareja

This study identifies liver-resident ILC1s as a critical barrier against breast cancer liver metastasis, showing that DR5 expression and host metabolism influence this immunosurveillance.

This paper develops a microfluidic tissue array platform for personalized drug screening using tumor explants or biopsies, showing reduced tumor cell viability and proliferative cell retention after treatment.

The paper develops Mosaic, a machine learning system that classifies tumors into detailed subtypes and identifies molecular phenotypes using histopathologic and genomic data from a large patient cohort.

This paper identifies eIF4A as a key regulator of ER translation in breast cancer and shows that inhibiting eIF4A, either alone or with fulvestrant, suppresses ER expression and tumor growth in advanced ER+ breast cancer.

This study identifies APOBEC3 mutagenesis as a common driver of therapy resistance in breast cancer, associated with poorer clinical outcomes.

This study demonstrates that RNA transcripts can serve as templates for double-strand break repair in human cells, identifying DNA polymerase-zeta as a key enzyme and revealing genomic scars associated with this process.

This paper develops a multimodal transformer model using H&E images and text reports to predict recurrence scores in hormone receptor-positive breast cancer, achieving high accuracy and generalizability.

The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.